tcsc0031495 Adavivint

Adavivint is a potent and selective inhibitor of canonical Wnt signaling, with an EC₅₀ of 19.5 nM via a high-throughput TCF/LEF-reporter assay in SW480 colon cancer cells.

IC50 & Target: EC50: 19.5 nM (Wnt, SW480 cell)^[1]

In Vitro: Adavivint (SM04690) is a potent and selective inhibitor of Wnt signaling, with an EC₅₀ of 19.5 nM via a high-throughput TCF/LEF-reporter assay in SW480 colon cancer cells, and shows no effect on SV40 luciferase reporter. Adavivint enhances aggregation of human mesenchymal stem cells (hMSCs) with an EC₅₀ of 10 nM. Adavivint (30 nM) protects chondrocytes from catabolic breakdown in vitro^[1].

In Vivo: Adavivint (0.3 μg) enhances cartilage repair and protection in the rat acute cruciate ligament tear and partial medial meniscectomy osteoarthritis (ACLT + pMMx OA) model^[1].